Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 601–700 of 1,002
Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 29
Kleber, K. T., Iranpur, K. R., Perry, L. M., Cruz, S. M., Razmara, A. M., Culp, W. T. N., Kent, M. S., Eisen, J. A., Rebhun, R. B., & Canter, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983344 · Cited by 23
Understanding and predicting the efficacy of FMT
Lavelle, A., & Sokol, H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01991-0 · Cited by 20
Gut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20
Exploring the roles of intestinal flora in enhanced recovery after surgery
Liu, Z., Li, N., Dang, Q., Liu, L., Wang, L., Li, H., & Han, X. (2023) · iScience · doi:10.1016/j.isci.2023.105959 · Cited by 25
Oh, M., & Zhang, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-31210-w · Cited by 24
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 26
Aging and cancer hallmarks as therapeutic targets
Wang, J., Wei, J., & Inuzuka, H. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0018 · Cited by 21
Abenavoli, L., Montori, M., Svegliati‐Baroni, G., Argenziano, M. E., Giorgi, F., Scarlata, G. G. M., Ponziani, F. R., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59081427 · Cited by 23
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment
Liu, X., Li, S., Wang, L., & Ma, K. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167230 · Cited by 22
Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma
Scarpellini, E., Scarlata, G. G. M., Santori, V., Scarcella, M., Kobyliak, N. M., & Abenavoli, L. (2024) · Biomedicines · doi:10.3390/biomedicines12081797 · Cited by 22
Simple and effective bacterial-based intratumoral cancer immunotherapy
Carroll, C., Andrew, E. R., Malik, L., Elliott, K. F., Brennan, M., Meyer, J., Hintze, A., Almonte, A. A., Lappin, C., Macpherson, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002688 · Cited by 20
Therapeutic Methods for Gut Microbiota Modification in Lipopolysaccharide-Associated Encephalopathy
Li, S., Guo, H., Xu, X., Hua, R., Zhao, Q., Li, J., Lv, J., & Li, J. (2021) · Shock · doi:10.1097/shk.0000000000001758 · Cited by 18
Rethinking the rise of early-onset gastrointestinal cancers: a call to action
Weinberg, B. A., Murphy, C. C., Freyer, D. R., Greathouse, K. L., Blancato, J. K., Stoffel, E. M., Drewes, J. L., Blaes, A. H., Salsman, J. M., You, Y. N., et al. (2025) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf002 · Cited by 20
Pomej, K., Frick, A. P., Scheiner, B., Balcar, L., Pajancic, L., Klotz, A., Kreuter, A., Lampichler, K., Regnat, K., Zinober, K., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321189 · Cited by 21
Hu, M., Zhu, X., Huang, X., Li, H., Lin, X., Zhang, H., Hu, Y., Tong, T., Li, L., Xuan, B., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115589 · Cited by 23
Nutrient acquisition of gut microbiota: Implications for tumor immunity
Wang, Y., Huang, J., Tong, H., Jiang, Y., Yu, J., & Ma, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.003 · Cited by 20
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100018 · Cited by 34
Fallarino, F., & Blank, C. U. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01222-w · Cited by 26
DiMaio, D., Emu, B., Goodman, A. L., Mothes, W., & Justice, A. C. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab212 · Cited by 24
Leigh, S., Lynch, C. M. K., Bird, B., Griffin, B. T., Cryan, J. F., & Clarke, G. A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2043849 · Cited by 19
Cao, Z., Wang, L., Liu, R., Lin, S., Wu, F., & Liu, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100311 · Cited by 23
Xu, L., Ma, Y., Fang, C., Peng, Z., Gao, F., Moll, J. M., Qin, S., Yu, Q., Hou, Y., Kristiansen, K., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.953884 · Cited by 20
Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
Mishra, S., Amatya, S. B., Salmi, S., Koivukangas, V., Karihtala, P., & Reunanen, J. (2022) · Cancers · doi:10.3390/cancers14205121 · Cited by 19
Xu, K., Cai, J., Xing, J. Q., Li, X., Wu, B., Zhu, Z., & Zhang, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-10307-x · Cited by 23
Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Zhang, X., Ishikawa, D., Ohkusa, T., Fukuda, S., & Nagahara, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1068567 · Cited by 19
Consistent Stool Metagenomic Biomarkers Associated with the Response To Melanoma Immunotherapy
Olekhnovich, E. I., Ivanov, A. B., Babkina, A. A., Sokolov, A. A., Игоревич, У. В., Fedorov, D. E., & Ilina, E. N. (2023) · mSystems · doi:10.1128/msystems.01023-22 · Cited by 21
Fecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
Self-citationBachour, S. P., Dalal, R. S., & Allegretti, J. R. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231165581 · Cited by 17
Vandoni, G., D’Amico, F., Fabbrini, M., Mariani, L., Sieri, S., Casirati, A., Guardo, L. D., Vecchio, M. D., Anichini, A., Mortarini, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411611 · Cited by 18
Microbes mediated immunogenic cell death in cancer immunotherapy
Huang, J., Duan, F., Xie, C., Xu, J., Zhang, Y., Wang, Y., Tang, Y., & Leung, E. L. (2023) · Immunological Reviews · doi:10.1111/imr.13261 · Cited by 20
Gut microbiome, metabolome and alopecia areata
Liu, Z., & Liu, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1281660 · Cited by 25
Coschi, C. H., & Juergens, R. A. (2023) · Current Oncology · doi:10.3390/curroncol31010001 · Cited by 26
Immune‐related adverse events of antibody‐based biological medicines in cancer therapy
Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 22
Bouferraa, Y., Chedid, A., Amhaz, G., Lakkiss, A. E., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158036 · Cited by 18
Nutrition and Cancer Risk from the Viewpoint of the Intestinal Microbiome
Tanaka, Y., Shimizu, S., Shirotani, M., Yorozu, K., Kitamura, K., Oehorumu, M., Kawai, Y., & Fukuzawa, Y. (2021) · Nutrients · doi:10.3390/nu13103326 · Cited by 23
Impact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome
Khodadoust, M. S., Mou, E., & Kim, Y. H. (2022) · Blood · doi:10.1182/blood.2020008241 · Cited by 22
Unlocking the power of the microbiome for successful cancer immunotherapy
Clavijo-Salomon, M. A., & Trinchieri, G. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011281 · Cited by 18
Susiriwatananont, T., Eiamprapaporn, P., Roque, M. V., Farraye, F. A., Pearlman, A., & Chumsri, S. (2025) · Cells · doi:10.3390/cells14221779 · Cited by 21
Zhang, Y., Xu, X., Wang, S., Yin, X., Zhang, B., Zhu, Z., Ji, R., Zhu, J., He, H., Cheng, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013823 · Cited by 29
Araji, G., Maamari, J., Ahmad, F. A., Zareef, R. O., Chaftari, P. S., & Yeung, S. J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-10 · Cited by 22
Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?
Lin, Y., Kong, D.-X., & Zhang, Y.-N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852194 · Cited by 17
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
Guardamagna, M., Berciano‐Guerrero, M., González, B. V., Pérez-Ruiz, E., Oliver, J., Lavado-Valenzuela, R., Rueda‐Domínguez, A., Barragán, I., & Queipo‐Ortuño, M. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911990 · Cited by 18
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 20
Golčić, M., Simetić, L., Herceg, D., Blažičević, K., Jovanović, G. K., Dražić, I., Belančić, A., Skočibušić, N., Palčevski, D., Rubinić, I., et al. (2023) · Cancers · doi:10.3390/cancers15113052 · Cited by 18
Jiang, S., Fu, W., Wang, S., Zhu, G., Wang, J., & Ma, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311222 · Cited by 21
Liu, G., Huang, W., Chen, L., Tayier, N., You, L., Hamza, M., Tian, X., Wang, H., Nie, G., Zhu, M., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101993 · Cited by 17
Camp, K. K., Coleman, M. F., McFarlane, T. L., Doerstling, S. S., Khatib, S. A., Rezeli, E. T., Lewis, A. G., Pfeil, A. J., Smith, L. A., Bowers, L. W., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.172868 · Cited by 19
Gut microbiota and immunotherapy of renal cell carcinoma
Bibbò, S., Porcari, S., Vecchio, L. E. D., Severino, A., Mullish, B. H., Ianiro, G., Gasbarrini, A., & Cammarota, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2268982 · Cited by 20
Polyphenolic Compounds: Orchestrating Intestinal Microbiota Harmony during Aging
Pereira, Q. C., Fortunato, I. M., Oliveira, F. D. S., Alvarez, M. C., dos Santos, T. W., & Ribeiro, M. L. (2024) · Nutrients · doi:10.3390/nu16071066 · Cited by 19
Li, W., Gu, J., Fan, H., Zhang, L., Guo, J., & Si, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104426 · Cited by 20
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Cui, L., Xu, X. H., Fan, H., Wan, X., Chen, Q., Zhang, J., Tao, C., Du, Z., Wang, S., Zhang, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217183 · Cited by 19
Fecal microbiota transplantation for the treatment of chronic inflammatory skin diseases
Wu, M., Chen, X., Lu, Q., & Yao, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37432 · Cited by 21
Cesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 25
Su, J., Chen, X., Xiao, Y., Li, D., Li, M., Li, H., Huang, J., Lai, Z., Su, Z., Xie, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.727082 · Cited by 17
How gut bacteria could boost cancer treatments
Erdmann, J. M. (2022) · Nature · doi:10.1038/d41586-022-01959-7 · Cited by 18
Zhao, W. (2024) · American Journal of Cancer Research · doi:10.62347/xkuj3012 · Cited by 17
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Shang, J., Valle, D. M. D., Britton, G. J., Mead, K., Rajpal, U., Chen-Liaw, A., Mogno, I., Li, Z., Menon, R., Gonzalez‐Kozlova, E., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232079 · Cited by 17
The mechanisms and therapeutic potential of the microbiome-immune interface in cancer
Christina, B., Poongkuzhali, S., Muninathan, N., Bhaskaran, K., & Suresh, A. (2025) · Discover Biotechnology · doi:10.1007/s44340-025-00031-0 · Cited by 18
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy
Jani, C., Edwards, K., Bhanushali, C. D., Zheng, X. X., Salazar, A. S., Lopes, G. D. L., Jr., & Watson, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713382 · Cited by 21
Cheng, X., Wang, J., Gong, L., Dong, Y., Shou, J., Pan, H., Yu, Z., & Fang, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185479 · Cited by 20
Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
Peng, X., Gong, C., Zhang, W., & Zhou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091088 · Cited by 18
Mattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Boicean, A., Bratu, D. G., Bacila, C. I., Tanasescu, C. A. H., Fleacă, R. S., Mohor, C. I., Comaniciu, A., Băluță, T., Roman, M. D., Chicea, R., et al. (2023) · Pathogens · doi:10.3390/pathogens12060766 · Cited by 17
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
Sarkar, J., Gomez, E. C., Oba, T., Chen, H., Dy, G. K., Segal, B. H., Ernstoff, M. S., & Ito, F. (2023) · World Journal of Oncology · doi:10.14740/wjon1587 · Cited by 20
Pang, S. A., Elkrief, A., Capella, M. P., & Miller, W. H. (2023) · Current Oncology · doi:10.3390/curroncol30090570 · Cited by 16
Boicean, A., Bratu, D. G., Fleacă, R. S., Vasile, G., Shelly, L., Bîrsan, S., Bacila, C. I., & Hasegan, A. G. (2023) · Pathogens · doi:10.3390/pathogens12091149 · Cited by 18
Lifestyle and host determinants of antitumor immunity and cancer health disparities
Swaby, A. M., Atallah, A., Varol, O., Cristea, A., & Quail, D. F. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.08.007 · Cited by 19
Role of the Microbiota in Skin Neoplasms: New Therapeutic Horizons
Savoia, P., Azzimonti, B., Rolla, R., & Zavattaro, E. (2023) · Microorganisms · doi:10.3390/microorganisms11102386 · Cited by 19
Manni, A., Sun, Y., Schell, T. D., Lutsiv, T., Thompson, H. J., Chen, K.-M., Aliaga, C. A., Zhu, J., & El‐Bayoumy, K. (2023) · Pharmaceuticals · doi:10.3390/ph16101422 · Cited by 19
Hoyd, R., Wheeler, C. E., Liu, Y., Singh, M. S. J., Muniak, M., Jin, N. Y., Denko, N. C., Carbone, D. P., Mo, X. M., & Spakowicz, D. J. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0435 · Cited by 16
Tang, L., Yang, X., Zhou, M., Feng, L., Ji, C., Liang, J., Zhang, B., Shen, R., & Wang, L. (2024) · mSystems · doi:10.1128/msystems.00138-24 · Cited by 20
Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome
Nguyen, N.-T. A., Jiang, Y., & McQuade, J. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409414 · Cited by 23
Zheng, J., & Chen, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429722 · Cited by 20
Impact of the Lung Microbiota on Development and Progression of Lung Cancer
Belaïd, A., Roméo, B., Rignol, G., Benzaquen, J., Audoin, T., Vouret‐Craviari, V., Brest, P., Varraso, R., von Bergen�, M., Marquette, C., et al. (2024) · Cancers · doi:10.3390/cancers16193342 · Cited by 18
Wu, J., Zhang, S., Yu, S., An, G., Wang, Y., Yu, Y., Liang, L., Wang, Y., Xu, X., Xiong, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53109-4 · Cited by 17
Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota
Green, G. B. H., Cox-Holmes, A. N., Potier, A. C. E., Marlow, G. H., & McFarland, B. C. (2024) · Biomedicines · doi:10.3390/biomedicines12112429 · Cited by 16
Intra-tumoral bacteria in breast cancer and intervention strategies
Hou, T., Huang, X., Lai, J., & Zhou, D. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115516 · Cited by 20
Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Zhang, Y., Mo, C., Ai, P., He, X., Xiao, Q., & Yang, X. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2454937 · Cited by 20
The interplay between gut bacteria and targeted therapies: implications for future cancer treatments
He, J., Chen, Y., Zhao, H., & Li, Y. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01108-6 · Cited by 21
Diop, K., Mbaye, B., Nili, S., Filin, A., Benlaïfaoui, M., Malo, J., Renaud, A. S., Belkaïd, W., Hunter, S., Messaoudene, M., et al. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00694-4 · Cited by 17
Koo, H., & Morrow, C. D. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02312-0 · Cited by 16
Pomej, K., Balcar, L., Scheiner, B., Semmler, G., Meischl, T., Mandorfer, M., Reiberger, T., Müller, C., Trauner, M., & Pinter, M. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s317957 · Cited by 17
Harnessing the microbiome to restore immunotherapy response
Bullman, S., Eggermont, A. M. M., Johnston, C. D., & Zitvogel, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00300-x · Cited by 17
Too much water drowned the miller: Akkermansia determines immunotherapy responses
Li, L., & McAllister, F. M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100642 · Cited by 21
Oey, O., Liu, Y.-Y., Sunjaya, A. F., Simadibrata, D. M., Khattak, M. A., & Gray, E. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i11.929 · Cited by 15
Febriyanto, T., Muhammad, F., Wijaya, W., Oey, O., & Simadibrata, D. M. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.11.017 · Cited by 20
Saha, S., Rehman, L., Rehman, A., Darbaniyan, F., Weber, D. M., Becnel, M., Gaballa, M., Thomas, S. K., Lee, H. C., Chang, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014476 · Cited by 16
Ji, S., Ahmad, F., Peng, B., Yang, Y., Su, M., Zhao, X., & Vatanen, T. (2025) · Microbiome · doi:10.1186/s40168-025-02046-5 · Cited by 22
Intratumoral microbiota: implications for cancer progression and treatment
Xie, Z., Wu, Z., Liu, Y., Gu, Y., Niu, J., & Lv, K. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1551515 · Cited by 23
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
Formelli, M. G., Palloni, A., Tavolari, S., Deiana, C., Andrini, E., Marco, M. D., Campana, D., Lamberti, G., & Brandi, G. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115671 · Cited by 20
Zhao, C., Li, S.-S., Yau, T. C. C., Chen, W., Ren, J., Guan, X., & Kong, F. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102370 · Cited by 19
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Keenan, B. P., Yadav, M., Ansstas, G., Fabrizio, D. A., Murugesan, K., Montesion, M., Niyogi, D. G., Mellman, I., & Melero, I. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1239 · Cited by 26
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
Li, Y., Wang, S., Lin, M., Hou, C., Li, C., & Li, G. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0927-0 · Cited by 15
The Microbiome in PDAC—Vantage Point for Future Therapies?
Pfisterer, N., Lingens, C., Heuer, C., Dang, L., Neeße, A., & Ammer‐Herrmenau, C. (2022) · Cancers · doi:10.3390/cancers14235974 · Cited by 15
Melanoma antigens recognized by T cells and their use for immunotherapy
Ohta, S., Misawa, A., Kyi‐Tha‐Thu, C., Matsumoto, N., Hirose, Y., & Kawakami, Y. (2023) · Experimental Dermatology · doi:10.1111/exd.14741 · Cited by 18
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.